IBT 13131 is primarily investigated for its potential therapeutic applications in the field of oncology. It functions as a selective inhibitor targeting specific pathways involved in cancer cell proliferation and survival. Researchers are exploring its efficacy in treating various types of cancers, particularly those resistant to conventional therapies. Its mechanism of action allows it to disrupt critical signaling pathways, potentially leading to reduced tumor growth and metastasis. Additionally, IBT 13131 is being studied for its role in combination therapies, where it may enhance the effectiveness of other anticancer agents. Preliminary studies suggest it could offer a promising approach for personalized cancer treatment, especially in cases with specific genetic mutations. Further clinical trials are essential to fully understand its safety profile and therapeutic potential.